Malignant Atrophic Papulosis - Causes, Symptoms, Diagnosis, and Treatment

Introduction:

Malignant atrophic papulosis is also referred to as Kohlmeier-Degos disease or Degos disease. It is a rare condition in which thrombo-obliterative vasculopathy can affect the skin, gastrointestinal tract, and central nervous system. It may be as diffuse, even causing major morbidity and mortality, in virtue of multiorgan involvement. There are two forms of the disease mentioned in the literature: one is the life-threatening systemic form, and the other is the benign monosymptomatic cutaneous form. Thus, the term atrophic papulosis is a more suitable name for the disease than malignant atrophic papulosis.

Atrophic papulosis is further classified as malignant atrophic papulosis (systemic involvement) and benign cutaneous disease (limited to the skin). The hallmark of the disease is papular skin lesions with central porcelain-white atrophy and a surrounding telangiectatic border, which is considered pathognomonic.

What Causes Malignant Atrophic Papulosis?

The etiology of malignant atrophic papulosis is not very well known. However, it has been established as a multifactorial disease that involves a genetic predisposition, immune dysfunction, and vascular abnormalities. Kohlmeier was the first to describe this illness in 1941, but its etiology still remains unknown. Several theories imply a genetic predisposition of family members to the disease, and more recently, cases have cited associations with complement pathway dysregulation. The inheritance was previously thought to be autosomal dominant, although no definitive genetic mutation has been consistently identified.

Apart from genetic manifestations, three hypotheses are suggested as the cause of malignant atrophic papulosis: coagulopathy, vasculitis, and a primary defect of the endothelial cells. These causes of atrophic papulosis are not mutually exclusive and may occur depending on environmental factors that create favorable conditions for disease progression. In addition, a few reports have pointed to infections and other external triggers as precipitating factors, though the evidence remains anecdotal.

Which Population Is Most Affected by Malignant Atrophic Papulosis?

Atrophic papulosis most commonly affects individuals in the second to fifth decades of life, though it can present at any age. The occurrence of atrophic papulosis in newborns is extremely rare. Although there is a slight female preponderance of the disease, it is not explicitly gendered, as cases are reported across both sexes. The systemic form is particularly aggressive in young adults, while older individuals are more prone to display the cutaneous form without internal organ involvement.

What Does Atrophic Papulosis Look Like?

The skin lesions in atrophic papulosis are highly distinctive. The lesions initially appear as erythematous papules measuring between 2.0 mm and 5.0 mm, usually on the trunk or extremities. With time, the lesions take a characteristic presentation, being centrally depressed papules with a porcelain-white atrophic center and a periphery of the telangiectatic rim.Histologically, the lesions show a wedge-shaped area of ischemic dermis (restricted blood flow) with a perivascular lymphohistiocytic infiltrate at the edge of the ischemic area. The overlying epidermis may show slight hyperkeratosis and atrophy.

In the early stages, the lesions can masquerade as lupus erythematosus or lichen sclerosis and, in later stages, mimic lichen simplex chronicus atrophicus. Thrombosis (the formation of a blood clot) within the affected area vessels leads to significant vascular damage, which is another diagnostic hallmark.

What Are the Symptoms of Malignant Atrophic Papulosis?

The cutaneous lesions of malignant atrophic papulosis begin as small erythematous papules and gradually develop into larger papules (0.2 to 0.4 inches) with a characteristic porcelain-white center and erythematous rim. Though these skin lesions are mostly asymptomatic or mildly pruritic, the real danger lies in their extracutaneous involvement.

In cases where there is extracutaneous involvement, systemic manifestations can appear suddenly or after years of cutaneous involvement. The gastrointestinal system is often involved, leading to symptoms such as abdominal pain, gastrointestinal bleeding, or perforation. Neurological symptoms can include numbness, tingling, seizures, or even strokes, depending on the areas of the central nervous system affected. Other organ systems, including cardiovascular, pulmonary, or even ocular systems, might be involved, so significant respiratory distress, changes in vision, or cardiac involvement might follow.

How to Diagnose Malignant Atrophic Papulosis?

Diagnosing malignant atrophic papulosis primarily depends on identifying the characteristic skin lesions during physical examination, followed by histopathological confirmation. Diagnosis is usually difficult, especially in the early stages, and systemic symptoms are not evident and can be nonspecific. As there is no serum marker or laboratory abnormality that is specifically associated with this illness, diagnosis is often delayed, and missed opportunities for early intervention are lost.

Organ-specific evaluations need to be performed in patients suspected of having extracutaneous involvement. For instance, gastrointestinal bleeding is investigated with fecal occult blood tests, endoscopy, and colonoscopy. Central nervous system involvement should be assessed with MRI.

What Is the Treatment for Malignant Atrophic Papulosis?

Unfortunately, no definitive treatment exists for malignant atrophic papulosis. However, several medications and anticoagulants help to facilitate blood perfusion. Cutaneous lesions have been managed successfully using various anticoagulants like Dipyridamole, Pentoxifylline, and Aspirin. However, this treatment does not prevent systemic progression.

Eculizumab, one of the recent developments of complement inhibitors, has been promising in managing and effectively postponing severe cases, with mainly systemic involvement, by reducing intestinal lesions. However, this is an expensive therapy that may not be effective at times, delaying disease progression. Subcutaneous administration of Treprostinil has been tried in cases where Eculizumab has proven ineffective, especially in patients with cerebral or intestinal manifestations. Immunosuppressive therapies like Cyclosporin A, Azathioprine, and corticosteroids have largely been unsuccessful.

Frequent monitoring is required since the disease might be potentially life-threatening and could be quite severe. Follow-up should occur at intervals of one year, even more frequently in severe instances, aiming to observe the appearance of new organ involvement or progression of existing symptoms.

Which Diseases Are Similar to Malignant Atrophic Papulosis?

Some diseases have been reported that mimic the cutaneous and systemic appearance of malignant atrophic papulosis. They include:

• Lupus Erythematosus: A systemic autoimmune disorderoccurring in various organs.

• Dermatomyositis: It is a disease characterized by muscle weakness and characteristic skin rashes.

• Atrophic Blanche: It appears as white, stellate atrophic scars with peripheral telangiectasias due to livedoid vasculopathy.

Conclusion

It is a rare but serious cutaneous and systemic condition known as malignant atrophic papulosis. The systemic type is dangerous because close follow-up and symptomatic management are required. No cure has yet been found, but an understanding of the complementary pathway and new therapeutic agents provides some comfort for better management of this serious condition.